Subcutaneous Administration of Modified Vaccinia Virus Ankara Expressing an Ag85B-ESAT6 Fusion Protein, but Not an Adenovirus-Based Vaccine, Protects Mice Against Intravenous Challenge with Mycobacterium tuberculosis

摘要: Recombinant virus-based tuberculosis (TB) vaccines that are strongly immunogenic and elicit robust cellular immunity considered ideal vaccine candidates. Here, we engineered a poxvirus-based vaccine, MVA85B-E6, an adenovirus-based AD85B-E6, both of which express the fusion protein Ag85B-ESAT6. Subcutaneous vaccination AD85B-E6 generated strong interferon (IFN)-γ production by CD4 CD8 T cells cytotoxic lymphocyte activity; these results indicate T-helper type 1 immune responses were elicited in mice, is contrast to moderate induced with MVA85B-E6. However, MVA85B-E6 given subcutaneously led levels protection comparable bacillus Calmette-Guerin lungs spleens, whereas did not show any protective efficacy after intravenous challenge BALB/c mice Mycobacterium H37Rv. Our study emphasizes more efficient biomarkers for appropriate routes administration necessary development successful TB vaccine.